Clinical data | |
---|---|
Trade names | DDAVP (deamino D-arginine vasopressin), Minirin, others |
AHFS/Drugs.com | Monograph |
Pregnancy category |
|
Routes of administration | IV, IM, SC, intranasal, by mouth, under the tongue |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | Variable; 0.08–0.16% (by mouth) |
Protein binding | 50% |
Elimination half-life | 1.5–2.5 hours |
Excretion | Kidney |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.037.009 |
Chemical and physical data | |
Formula | C46H64N14O12S2 |
Molar mass | 1069.22 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Desmopressin, sold under the trade name DDAVP among others, is a medication used to treat diabetes insipidus, bedwetting, hemophilia A, von Willebrand disease, and high blood urea levels.[1] In hemophilia A and von Willebrand disease, it should only be used for mild to moderate cases.[1] It may be given in the nose, by injection into a vein, by mouth, or under the tongue.[1]
Common side effects include headaches, diarrhea, and low blood sodium.[1] The low blood sodium that results may cause seizures.[1] It should not be used in people with significant kidney problems or low blood sodium.[1] It appears to be safe to use during pregnancy.[1] It is a synthetic analogue of vasopressin, the hormone that plays roles in the control of the body's osmotic balance, blood pressure regulation, kidney function,[2] and reduction of urine production.[1]
Desmopressin was approved for medical use in the United States in 1978.[1] It is on the World Health Organization's List of Essential Medicines.[3] It is available as a generic medication.[1]